CNC vs KYTX · P/E 8.4, rev $103.52B vs $488.8M cap
Centene Corp (CNC) versus Kyverna Therapeutics, Inc. Common Stock (KYTX) — a side-by-side from cached financials, not a winner call.
Centene Corp (CNC) is a healthcare plans company listed on US.
Kyverna Therapeutics, Inc. Common Stock (KYTX) is a biotechnology company listed on NASDAQ.
Latest reported CNC revenue for 2026-06-30 was $103.52B. Net income was $2.63B. CNC currently screens at market cap $28.19B and trailing P/E 8.4.
KYTX does not have a complete income-statement cache yet.
CNC currently screens at market cap $28.19B and trailing P/E 8.4. KYTX currently screens at market cap $488.8M.
Not investment advice. Open the CNC and KYTX stock pages for the full models.
Not investment advice.